Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel
2022 ASCO Annual Meeting
Mairéad G. McNamara, PhD, MBBCh, of The Christie NHS Foundation Trust, discusses phase II findings of the NET-02 trial, which explored an unmet need in the second-line treatment of patients with progressive, poorly differentiated extrapulmonary neuroendocrine carcinoma. In the trial, the combination of liposomal irinotecan, fluorouracil, and folinic acid, but not docetaxel, met the primary endpoint of 6-month progression-free survival rate (Abstract 4005).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The prognosis for patients with poorly differentiated neuroendocrine carcinoma, which is extrapulmonary is poor. Most of these patients present with advanced disease and their prognosis is usually less than a year. The treatment for these patients is predominantly like small cell lung cancer or lung neuroendocrine carcinoma. With these patients with extra pulmonary neuroendocrine carcinoma, they have an aggressive histology with a KI67, by definition being greater than 20%. The treatment in the first line advanced setting has been a platinum based treatment for the last 30 years and there's no standard treatment for a second line, and this is an area of unmet need. And therefore the NET-02 trial addresses this unmet need. In the NET-O2 trial, one of the treatment arms is liposomal irinotecan 5-fluorouracil folinic acid. This has been found and has been reported to increase intratumoral levels of irinotecan and SN-38, which is the active metabolite of irinotecan. The second arm in NET-02 trial is docetaxel, which has been used as a standard of care option in small cell lung carcinoma as per the NCCN guidelines. The key eligibility for this study was that patients should have extrapulmonary neuroendocrine carcinoma grade 3. With a KI67 of greater than 20% have received previous platinum based treatment and have an equal performance status of less than or equal to two. The primary endpoint for this study was six month PFS rate, with secondary endpoints being response rate, PFS, overall survival, toxicity, quality of life and translational endpoints. The quality of life and translational endpoint results will be presented at a later date. So patients had scans every eight weeks and continued on treatment until progressive disease or intolerable toxicity. The statistical design was allowing for a 5% dropout rate. There was an 80% power to detect the one-sided 95% confidence interval for the six month PFS rate and excluding 15% with the true rate being greater than 30%. So if a patient had a six month PFS rate of 30% or greater, that was the required level of efficacy, and a rate of 15% or less give grounds for rejection. These rates were based on review of retrospective data where the six month PFS rate was reported and ranged from 15% to 25%. So at a median follow up of 8.1 months, the six month PFS rate was, primary endpoint was met by liposomal irinotecan 5-fluorouracil with the six month PFS rate of being 31% with a 95% lower confidence limit of 17.25% and exceeding the rate of 15%, which was gave grounds for rejection. For docetaxel, the six month PFS rate was 13.8%, with a lower confidence limit of 4.85%. The median PFS for liposomal irinotecan was three months versus two for docetaxel. Median overall survival was nine months versus five for docetaxel. And the response rate was similar in both arms 10.3%. So in conclusion, the primary end point of six month PFS rate was met by liposomal irinotecan 5-fluorouracil folinic acid, but not docetaxel, exceeding the required threshold for efficacy. And the response rate was similar in both arms. The median overall survival was greater in the liposomal irinotecan arm, with the median overall survival of nine months versus five months with the docetaxel. The adverse events, the toxicity was similar with no new safety signals and based on these results, liposomal irinotecan warrants further exploration in these patients with extrapulmonary, poorly differentiated neuroendocrine carcinoma. And it would be important that guidelines would be developed using trial based evidence for these patients.
Related Videos
The ASCO Post Staff
Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial, the first prospective study to test the superiority of panitumumab vs bevacizumab in combination with standard doublet first-line chemotherapy for patients with RAS wild-type and left-sided metastatic colorectal cancer. The study showed that panitumumab improved overall survival in combination with mFOLFOX6, which may establish a standard first-line combination regimen for this population (Abstract LBA1).
The ASCO Post Staff
Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses his study findings, showing that germline genetic testing influenced care for patients with prostate cancer. Men whose genetic test was positive for a pathogenic germline variant received more recommendations for changes to follow-up and treatment, and for testing and counseling of relatives, than did patients with negative or uncertain test results (Abstract 10500).
The ASCO Post Staff
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses phase III findings from the KEYNOTE-716 study. The trial showed that compared with placebo, adjuvant pembrolizumab significantly improved distant metastasis–free survival in patients with resected stage IIB and IIC melanoma. The findings also suggest a continued reduction in the risk of recurrence and a favorable benefit-risk profile (Abstract LBA9500).
The ASCO Post Staff
Manali I. Patel, MD, MPH, of Stanford University School of Medicine, discusses clinical trial findings on the best ways to integrate community-based interventions into cancer care delivery for low-income and minority populations. Such interventions may improve quality of life and patient activation (often defined as patients having the knowledge, skills, and confidence to manage their health), as well as reduce hospitalizations and the total costs of care (Abstract 6500).
The ASCO Post Staff
Stephen M. Ansell, PhD, MD, of Mayo Clinic, discusses updated data from the ECHELON-1 trial, which showed that, when administered to patients with stage III or IV classical Hodgkin lymphoma, the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine resulted in a 41% reduction in the risk of death. These outcomes, says Dr. Ansell, confirm A+AVD as a preferred option for previously untreated disease (Abstract 7503).